{"changes":[],"country":"US","description":"Halo Biosciences develops disease-modifying drugs that target hyaluronan-mediated extracellular-matrix remodelling, with H1614 as lead candidate. Indications include Group 3 pulmonary hypertension, interstitial lung disease, pulmonary fibrosis, and liver fibrosis. The mechanism is positioned as first- and best-in-class for ECM-driven inflammation and fibrosis.","domain":"halobiosciences.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","investors":[],"lat":37.444329,"lng":-122.159847,"location":"PALO ALTO, California","name":"HALO BIOSCIENCES INC","rounds":[{"amountQuarantined":false,"amountUsd":2993376,"currency":"USD","date":"2024-01-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"halobiosciences-com","sources":[{"fact":"round","publisher":"sbir","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"halobiosciences.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://halobiosciences.com"},{"fact":"description","publisher":"halobiosciences.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://halobiosciences.com"}],"stage":null,"techStack":["GoDaddy Website Builder 8.0.0000","PayPal","Vercel Speed Insights","React"],"totalRaisedUsd":2993376,"updatedAt":"2026-05-02"}